[ Reply | Next | Previous | Up ]
From: Edgediagaws
Date: 03 Jul 2008
Time: 10:00:54 -0500
Remote Name: 193.53.87.71
<a href=http://www.drugs.com/news/emea-recommends-new-warning-epoetins-their-cancer-patients-8359.html>LONDON, Junme 11, 2008-The Europeazn Medicines</a> power (EMEA) has recommended updating thew yield intelligence for epoetin-containign medicines with a new indication for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients hardship cancer. Epoetin-containing medicines are indicated in patients with persistent <a href=http://www.blogotop.com/achetercialis>acheter ivagra generique</a> non-starter and for the treatment of anaemia in symptomatic patients with non-myeloid growths receiving chemotherapy. The power’s cabinet for sanative Products for Good Samaritan Use (CHMP) had periodicaled new materials from studies that showed an increased hazard of growth <a href=http://www.blogotop.com/achetercialis>achat viagra generique</a> movement forward, venous thromboembolism and sorter all-inclusive <a href=http://www.google.com/search?hl=en&q=survival+in+cancer+patients&btnG=Google+Search>survival in cancer patients</a> who admitd epoetins compared ot patients who did not admit them. Following this nottice, the CHMP concluded, at its June 2008 confterence, that the improves of epoetins persist <a href=http://asmforum.fr/index.php?showuser=6911>acheter calis generique</a> surpass ttheir endangers in the approved indications. on the other hand, in cancer patients with a reasonably great existence-expectancy, the gain of sing epoetins does not surpass the hazard <a href=http://www.blogotop.com/viagracialislevitra>acha levitra generique</a> growth ascension and shorter inclusiev survival and conseqqueently the cabinet concluded that in these patients anaemia should be corrected with blood transfusions.